Premium
The Bentiromide Test for Pancreatic Exocrine Insufficiency
Author(s) -
Toskes Phillip P.
Publication year - 1984
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1984.tb03322.x
Subject(s) - exocrine pancreatic insufficiency , medicine , cystic fibrosis , pancreatic function , gastroenterology , sweat test , pancreas , pancreatic disease , outpatient clinic , disease , urine
The bentiromide test, a test of pancreatic exocrine function, has recently been approved for clinical use by the Food and Drug Administration. The test has been studied in adult patients with chronic pancreatic disease and in children with cystic fibrosis. The 500‐mg dose and 6‐hour urine collection period appear optimal for separating patients with chronic pancreatic disease from control subjects. Side effects with the 500‐mg dose are virtually nonexistent. This simply performed outpatient test of chymotrypsin function appears to be an excellent means of confirming the diagnosis of pancreatic exocrine insufficiency.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom